Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy; the iFOCUS Study
Latest Information Update: 23 Feb 2026
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms iFOCUS
Most Recent Events
- 18 Feb 2026 Status changed from active, no longer recruiting to recruiting.
- 07 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2024 Status changed from not yet recruiting to recruiting.